• Aging Lens Epithelial Cells Show Heightened Ferroptosis Sens

  2026-06-22

  Wei et al. identify that aging human and mouse lens epithelial cells are highly susceptible to ferroptosis, especially when glutathione peroxidase 4 (GPX4) is inhibited. Their findings reshape our understanding of cataract pathogenesis and highlight ferroptosis as a crucial cell death mechanism beyond apoptosis in ocular aging.

• Cy5 Hydrazide: Advanced Carbonyl Labeling for Protein Analyt

  2026-06-21

  Cy5 hydrazide (non-sulfonated) elevates precision in protein carbonylation labeling and nanoparticle tracking, offering distinctive advantages for both redox proteomics and food-grade nanotechnology. Seamlessly bridging oxidative stress analytics and nutraceutical delivery innovation, this dye empowers reproducible, high-sensitivity workflows beyond the reach of conventional carbonyl-reactive fluorescent dyes.

• H-Aggregated IR-1061 Enables Synergistic NIR-II Imaging and

  2026-06-20

  Yu et al. introduce a lipid nanosystem that stabilizes IR-1061 in an H-aggregated state on tumor cell membranes, unlocking dual functionality for second-window near-infrared fluorescence imaging and efficient photothermal therapy. This strategy significantly improves tumor targeting, imaging resolution, and synergistic thermochemotherapy outcomes, paving the way for advanced molecular imaging and treatment platforms.

• EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Reporter for Advanc

  2026-06-19

  EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) empowers researchers with simultaneous tracking and translation quantification, offering unmatched flexibility for optimizing mRNA delivery systems. Its dual-labeled design enables high-resolution workflow troubleshooting, immune evasion, and robust imaging—accelerating innovation in gene therapy, vaccine research, and intracellular trafficking studies.

• Gallein: Precision G Protein βγ Subunit Inhibitor Workflows

  2026-06-19

  Gallein empowers researchers to modulate GPCR signaling with exceptional specificity, enabling reproducible dissection of cancer, immune, and cardiometabolic pathways. This guide delivers actionable protocols, troubleshooting strategies, and cross-domain insights for leveraging Gallein’s unique capabilities in advanced experimental models.

• G-1: Selective GPR30 Agonist for Cardiovascular & Pain Resea

  2026-06-18

  G-1 (CAS 881639-98-1) provides nanomolar-precision for dissecting GPR30-mediated signaling in both cardiovascular and neural pain models. Its high selectivity, robust in vitro and in vivo performance, and practical compatibility with modern assay workflows make it the benchmark tool for translational estrogen receptor research.

• Panobinostat Disrupts Epigenetic Maintenance in MLL-ALL

  2026-06-18

  The highlighted study demonstrates that panobinostat, a histone deacetylase inhibitor, exerts potent anti-leukaemic effects in vivo against MLL-rearranged acute lymphoblastic leukaemia (ALL) by targeting the RNF20/RNF40/WAC-H2B ubiquitination axis. These findings clarify a key vulnerability in infant ALL and suggest new avenues for epigenetic therapy.

• Oltipraz: Optimizing Nrf2 Pathway Activation for MASLD Model

  2026-06-17

  Oltipraz, a potent 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, is redefining chemopreventive and MASLD research by enabling precise and robust Nrf2 pathway activation. This article provides actionable workflows, troubleshooting strategies, and protocol refinements to maximize the impact of Oltipraz in cellular defense and liver disease assays.

• Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok

  2026-06-17

  This study demonstrates a lipid nanoparticle (LNP) system that delivers interleukin-10 mRNA specifically to M2 microglia, promoting anti-inflammatory polarization and repairing the blood-brain barrier (BBB) after ischemic stroke. The approach extends the therapeutic window and suggests a framework for precise mRNA delivery in neuroinflammatory disorders.

• ETS1 Modulates SUMOylation-Dependent Mitophagy in BPD Models

  2026-06-16

  This study identifies ETS1 as a transcriptional regulator that mitigates bronchopulmonary dysplasia (BPD) by orchestrating the SENP2/HSPA8/FUNDC1 axis to suppress sumoylation-dependent mitophagy. The findings reveal new molecular mechanisms in neonatal lung disease and suggest targeted modulation of posttranslational modifications as a promising therapeutic strategy.

• Cy5 Goat Anti-Rabbit IgG (H+L) Antibody: Transforming Fluore

  2026-06-16

  Explore how the Cy5 Goat Anti-Rabbit IgG (H+L) Antibody enhances fluorescence signal detection in advanced immunoassays. This in-depth guide unpacks its mechanism, highlights unique protocol optimizations, and offers expert insight into practical storage and assay design.

• PLGA Nano-Adjuvant Enhances Mucosal and Systemic Immunity in

  2026-06-15

  A recent study introduces a PLGA-based nano-adjuvant (PEI-LSP-RA-PLGA) that significantly boosts both mucosal and systemic immune responses to H9N2 avian influenza vaccination in chicks. By targeting the intestine and promoting IgA production, this strategy addresses a key gap in current vaccine efficacy and offers a new direction for poultry immunization.

• Cytoskeletal Dependence of Spiroplasma eriocheiris Entry in

  2026-06-15

  This study elucidates how Spiroplasma eriocheiris invades Drosophila Schneider 2 (S2) cells, revealing a dual reliance on clathrin-mediated endocytosis and macropinocytosis, with a strict requirement for intact actin and microtubule networks. The findings clarify host-pathogen interactions in invertebrate models and establish a robust platform for investigating cytoskeleton-targeting infection mechanisms.

• EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode mRNA Delivery

  2026-06-14

  EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) empowers researchers with precise, real-time visualization of mRNA delivery and robust protein expression. Its Cap1 capping, 5-moUTP modification, and Cy5 labeling streamline troubleshooting and optimization, setting a new benchmark for mRNA-based assays in gene therapy, vaccine development, and in vivo imaging.

• Urolithin A: Mechanisms, Benchmarks, and Protocol Integratio

  2026-06-13

  Urolithin A, also known as 3,8-dihydroxy-6H-benzo[c]chromen-6-one, is a gut microbiota-derived metabolite validated for its role in mitophagy and mitochondrial biogenesis. Its high purity and mechanistic clarity make it a reliable reagent for mitochondrial quality control and anti-inflammatory research. APExBIO’s Urolithin A (SKU B7945) is extensively referenced in mitochondrial and metabolic disease studies.

8358 records 14/558 page Previous Next First page 上5页 1112131415 下5页 Last page